Boehringer Ingelheim plans PhIII chronic kidney disease trial for aldosterone-targeting drug after mid-stage success
Boehringer Ingelheim’s aldosterone synthase inhibitor reached the primary endpoint of a mid-phase chronic kidney disease trial in combination with its Eli Lilly-partnered drug Jardiance. Boehringer is now gearing up for a large registrational trial to start next year.
Aldosterone synthase is an enzyme responsible for making aldosterone, and high levels of this hormone drive organ inflammation and fibrosis that can lead to conditions such as CKD and heart failure. The placebo-controlled Phase II trial studied multiple doses of Boehringer’s aldosterone synthase inhibitor, dubbed BI 690517, with or without Jardiance in 714 CKD patients receiving stable background therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.